MiRNAs are short 21-24-nucleotide (nt) RNA species that act as key regulators of gene expression and are expressed in the vast majority of eukaryotes, including humans. miRNA genes are transcribed from the genomes of nucleated cells into primary miRNAs (pri-miRNAs), which are trimmed into miRNA precursors (pre-miRNAs) by the nuclear RNase III Drosha 1 , acting together with the DiGeorge syndrome critical region 8 (DGCR8) protein within the microprocessor complex [2] [3] [4] . After export to the cytoplasm, the resulting ~60-70-nt pre-miRNAs are processed by the RNase III Dicer 5-7 . Assisted by TAR RNA-binding protein 2 (TRBP2) 8 , Dicer cleaves the stem of pre-miRNA substrates at the base of the loop to generate miRNA-miRNA* duplexes. The mature miRNAs are subsequently incorporated into effector ribonucleoprotein (RNP) complexes containing Argonaute 2 (Ago2) 9 and fragile X mental retardation protein (FMRP) 10 , guiding the miRNPs for the regulation of specific mRNAs, as reviewed previously 11, 12 . miRNAs regulate mRNA translation through recognition of binding sites of imperfect complementarity, in which pairing of miRNA nucleotides 2 to 8, or the seed region, is crucial. miRNAs have been predicted to regulate between 30% and 92% of the genes in humans 13, 14 , and to control numerous biological processes 15 , including the megakaryocytic differentiation of CD34 + hematopoietic progenitor cells 16 .
a r t i c l e s
MiRNAs are short 21-24-nucleotide (nt) RNA species that act as key regulators of gene expression and are expressed in the vast majority of eukaryotes, including humans. miRNA genes are transcribed from the genomes of nucleated cells into primary miRNAs (pri-miRNAs), which are trimmed into miRNA precursors (pre-miRNAs) by the nuclear RNase III Drosha 1 , acting together with the DiGeorge syndrome critical region 8 (DGCR8) protein within the microprocessor complex [2] [3] [4] . After export to the cytoplasm, the resulting ~60-70-nt pre-miRNAs are processed by the RNase III Dicer [5] [6] [7] . Assisted by TAR RNA-binding protein 2 (TRBP2) 8 , Dicer cleaves the stem of pre-miRNA substrates at the base of the loop to generate miRNA-miRNA* duplexes. The mature miRNAs are subsequently incorporated into effector ribonucleoprotein (RNP) complexes containing Argonaute 2 (Ago2) 9 and fragile X mental retardation protein (FMRP) 10 , guiding the miRNPs for the regulation of specific mRNAs, as reviewed previously 11, 12 . miRNAs regulate mRNA translation through recognition of binding sites of imperfect complementarity, in which pairing of miRNA nucleotides 2 to 8, or the seed region, is crucial. miRNAs have been predicted to regulate between 30% and 92% of the genes in humans 13, 14 , and to control numerous biological processes 15 , including the megakaryocytic differentiation of CD34 + hematopoietic progenitor cells 16 .
Released into the blood stream from bone marrow megakaryocytes, circulating blood platelets are central players involved in various pathophysiological conditions, such as cardiovascular diseases (proliferative, thrombotic and occlusive), inflammation and possibly cancer, causing substantial morbidity and mortality. Platelets are devoid of a nucleus and lack genomic DNA, but are nevertheless capable of protein synthesis. They were shown to contain rough endoplasmic reticulum and ribosomes 17 , to incorporate 14 C-labeled leucine into proteins 18 and to retain a small amount of poly(A) + RNA from their megakaryocyte progenitor cells 19 , sufficient to support de novo B cell lymphoma-3 (Bcl-3) 20 and thromboxane A 2 (TxA 2 ) 21 protein synthesis. In fact, between 15% and 32% of protein-coding genes are represented in the form of mRNAs in platelets [22] [23] [24] . A strong correlation between transcript abundance and protein expression has been observed 23, 24 , supporting the functionality of these platelet transcripts.
Important insights have emerged recently on the regulatory control of gene expression in human platelets, as the maturation of interleukin-1β 25 and tissue factor 26 mRNAs has been reported to occur through mRNA splicing. Raising important issues on the translational control of the mature mRNAs present in human platelets, these observations prompted us to ask whether circulating platelets harbor a gene-regulatory pathway based on miRNAs. Primarily using purified human platelets, we were able to demonstrate the existence of a competent miRNA pathway in these anucleate elements of the cardiovascular system.
RESULTS

Platelets contain an abundant and diverse array of miRNAs
Because platelet preparations are often contaminated by leukocytes, and given that a single platelet contains ~12,500-fold less mRNA than a nucleated cell 27 , we first established a procedure that consistently yielded highly purified human platelets. Analysis of our platelet preparations by reverse transcriptase-polymerase chain reaction (RT-PCR) amplification of the leukocyte marker CD45 mRNA, in parallel with that of the platelet-specific gene product glycoprotein IIb (GPIIb), indicated a marked depletion of leukocytes from the starting platelet-rich plasma (PRP) (Fig. 1a) , which we confirmed by hemocytometer counting (Fig. 1b) . We estimated the level of leukocyte RNA contamination to be <0.4%, yielding a degree of purity that was sufficient to permit a reliable interpretation of our platelet data and ~30-fold higher than that found to allow platelet RNA profiling analyses with no interference by contamination 28 .
a r t i c l e s
Our initial characterization of the total RNA content of platelets suggested a relatively low abundance of mRNA transcripts as compared to megakaryocytes (Fig. 1c) or neutrophils (data not shown). On the other hand, as for megakaryocytes, platelets seem to contain a well-defined population of small RNAs (Fig. 1c, left) . Locked nucleic acid (LNA)-based microarray profiling positively identified more than 170 different miRNAs, or 42.7% of the 398 miRNA probes that could be analyzed, in human platelets (Fig. 1d) , covering a range of ~2.5 log in expression levels (Supplementary Table 1 ). An additional 49 miRNAs, unpublished at the time of analysis, were also positively detected ( Supplementary Fig. 1 ), bringing the number of known platelet miRNAs to 219. Comparative analysis unveiled a subset of miRNAs that were differentially expressed among platelets, megakaryocytes and neutrophils, most of which were found to be more abundant in platelets (Supplementary Fig. 2 ). In addition, the differential miRNA profile of platelets compared to neutrophils ( Supplementary  Fig. 3 ) further supported the lack of leukocyte contribution to the platelet miRNA signals.
We confirmed the microarray profiling data of four selected miRNAs, present at various levels in platelets, by northern blotting (Fig. 1e) . The northern signals were proportional to the microarray relative fluorescence intensity (RFI), thereby establishing a good correlation between the two hybridization methods. By northern blotting, we could also exclude the possibility that the signal might have originated from the miRNA sequence embedded within pre-miRNA or pri-miRNA precursor molecules. We detected relatively strong signals corresponding to ~22-24-nt mature miRNAs in platelets, as compared to human embryonic kidney 293 (HEK293), HeLa and megakaryocytic cells (Fig. 1e, below) , for the four selected miRNAs.
On the basis of the variety and relative abundance of their miRNA content, platelets may represent one of the richest sources of human miRNAs reported to date.
In the case of the three most abundant miRNAs (miR-223, let-7c and miR-19a), the presence of bands in the ~70-nt range corresponding to pre-miRNA species was more readily detectable in cells other than platelets, upon a prolonged exposure of the blots (Fig. 1e, above) . The band migrating slightly above that corresponding to the pre-miRNA species of miR-223 and let-7c may be due to modifications, such as uridylation 29 ; however, this possibility requires further analysis. It is possible that the ~32-34-nt miR-223 and let-7c RNA species represent intermediates containing loop sequences resulting from asymmetrical processing of the pre-miRNA substrate 30 , although this remains to be tested. This miRNA profile supports a scenario in which pre-miRNAs would serve as a template for platelet miRNA synthesis. prepared from purified platelets upon incubation with 32 P-labeled human let-7a-3 pre-miRNA 30 . (c) Extracts from purified platelets were separated by gel filtration on a Superose 6 column, and the fractions were analyzed by western blotting using anti-Dicer antibody, as described 6, 10 . Selected (odd) fractions were tested for Dicer activity as in b. (d) Immunoblot analysis of TRBP2 IP derived from platelet extracts by using an anti-Dicer antibody. (e) Dicer processing activity assays on IP derived from platelet extracts using anti-TRBP2, control IgG or anti-Dicer antibodies. S10, 10,000g supernatant fraction. 
Pre-miRNA conversion into miRNA in platelet extracts
In support of our assertion that pre-miRNAs serve as a template for platelet miRNA biogenesis, we were able to detect the known protein components of the pre-miRNA processing complex-that is, Dicer and TRBP2, as well as Ago2, the core component of miRNA effector complexes, in human platelets (Fig. 2a) . We used confocal immunofluorescence microscopy to confirm the intraplatelet localization of Dicer and Ago2 ( Supplementary Fig. 4 ). In contrast, we could not detect the nuclear microprocessor components Drosha (Fig. 2a) and DGCR8 ( Fig. 2a and Supplementary Fig. 4 ) in platelets, a result that is consistent with their anucleate nature. Next, we assessed whether platelet Dicer is functional and capable of synthesizing miRNAs from pre-miRNAs in RNase activity assays using 32 P-labeled pre-let-7a-3. When incubated in the presence of platelet S10 extracts or Dicer immunoprecipitates, this typical Dicer substrate was converted into miRNA-sized RNA species (Fig. 2b) .
To characterize further the miRNA biosynthetic complex of platelets, we analyzed platelet extracts by gel filtration chromatography. These analyses revealed a pre-miRNA processing activity that cofractionated with a peak of Dicer corresponding to a protein complex of ~440 kDa (Fig. 2c) . Dicer and TRBP2 co-immunoprecipitated from human platelets (Fig. 2d) as a complex that was catalytically active in processing of pre-miRNA into miRNA (Fig. 2e) . Similar to those obtained in megakaryocytes (Supplementary Fig. 5 ), these data support the presence of Dicer-TRBP2 complexes that are capable of miRNA biogenesis in platelets.
Platelet miRNAs can mediate RNA silencing
We examined the ability of human platelet miRNAs to mediate sequence-specific gene silencing in assays measuring RNA-induced silencing complex (RISC) activity. Incubation of platelet extracts in the presence of a 32 P-labeled miR-223 sensor transcript, bearing a sequence that was perfectly complementary to endogenous miR-223, led to the accumulation of a 5′ end-labeled 39-nt RNA species (Fig. 3a, left) . We obtained similar results when using extracts from megakaryocytes ( Supplementary Fig. 6 ). These data are in agreement with Ago2-mediated cleavage of the sensor sequence that lies 10 nt from the 5′ end of the small RNA guide 31 . This activity was optimal at 30 °C (Fig. 3a, middle left) and sensitive to proteinase K (Fig. 3a, middle right) and EDTA (EDTA) (Fig. 3a, right) treatment, further supporting the idea that the Mg 2+ -dependent Ago2 enzyme is the RISC nuclease acting in platelets. We also validated the genesilencing properties of three additional miRNAs using specific 32 Plabeled sensor transcripts in platelet extracts and observed that the silencing activity of these miRNAs was proportional to their levels in platelets (Fig. 3b) .
Characterization of the endogenous miRNA effector complexes by gel filtration chromatography unveiled enrichment of relatively low-molecular-weight fractions for Ago2 and miR-223 (Figs. 3c,d) , concomitant with a platelet-derived miR-223 sensor cleavage activity (Fig. 3e) . We obtained similar results in megakaryocytes (Supplementary Fig. 7 ). Let-7c showed a fractionation profile similar to that of miR-223 (Fig. 3c) . The composition of miRNA effector complexes in platelets may be distinct from human Ago2 complexes of higher molecular weight detected in HeLa cells ( Supplementary  Fig. 8 ), which may also contain Dicer and TRBP2 (ref.
8).
Platelets harbor functional Ago2-miRNA complexes To verify the association between Ago2 and the mature form of endogenous miR-223, we carried out northern blot analysis of platelet Ago2 immunoprecipitates (Fig. 3f) . The implication of platelet Ago2 in gene silencing was confirmed upon detection of RISC activity in Ago2 immunoprecipitates (Fig. 3g) , whereas the role of miR-223 in guiding the effector complex was inferred by the inhibitory effects of an antisense RNA to miR-223 in platelet extracts (Fig. 3h) and by disrupting pairing at the cleavage site (Fig. 3i, lane  2) or of the miR-223 seed region (Fig. 3i, lane 3) . Together, these data suggest that miRNA-associated Ago2 proteins, in a complex reminiscent of recombinant RISC 32 , may form the endogenous miRNA effector complex in platelets. 
r t i c l e s
Ago2-miR-223 complexes may regulate P2Y 12 expression
We browsed the miRBase Target Database and identified a putative binding site for miR-223 in the 3′ untranslated region (3′ UTR) of the mRNA encoding P2Y 12 (Fig. 4a) . This purinergic receptor is known to amplify aggregation induced by all known platelet agonists. With P2Y 12 present in platelets at both the protein and mRNA level (Fig. 4b) , our next aim was to validate the functionality of the predicted miR-223-binding site in the context of the full-length P2Y 12 mRNA 3′ UTR. For that purpose, we used a reporter gene activity assay that involved coexpression of pre-miR-223 with a reporter construct containing the P2Y 12 3′ UTR, either wild-type or mutated in the miR-223-binding site seed region, as depicted in Figure 4a , in the HEK293 cell line, which does not express miR-223 (Fig. 1e, left) . In these experiments, disruption of miR-223 pairing to the P2Y 12 3′ UTR impaired its ability to repress gene expression (Fig. 4c, left) , implying a role for miR-223 in regulating P2Y 12 expression. We obtained similar results using reporter constructs in which the Renilla luciferase (Rluc) gene is placed under the control of the isolated miR-223 binding site, either wild-type or mutated in its seed region, in HEK293 cells (Fig. 4c, middle) as well as in megakaryocytes (Fig. 4c, right) . These experiments showed that miR-223 can regulate expression of mRNAs harboring a miR-223 regulatory element in platelet precursor cells. A role for miRNAs, such as miR-223, in regulating P2Y 12 expression is further supported by the presence of platelet P2Y 12 mRNA in Ago2 immunoprecipitates (Fig. 4d) , which constitutes an established biochemical approach for the identification of miRNA pathway targets in human cells 33 . P2Y 12 mRNA may thus serve as a template for de novo P2Y 12 protein synthesis in a process that may be regulated by Ago2-miR-223 complexes within human platelets.
DISCUSSION
In the present study, we have established the existence and functionality of miRNA pathway components in human platelets. Harboring a small, but diverse, transcriptome that represents up to one-third of all protein-coding genes in human 24 , these anucleate elements of the cardiovascular system contain abundant quantities of miRNAs. Our findings confirm previous studies reporting the presence of miRNAs in PRP samples, which may be prone to leukocyte contamination, prepared either from healthy donors 34 or patients with polycythemia vera 35 . The relative abundance of platelet miRNAs translates into a markedly increased miRNA/mRNA ratio versus nucleated cells of the hematopoietic system. Considering that the regulatory effect of miRNAs is dependent on the number of miRNA binding sites occupied in a given mRNA target, it is tempting to speculate that the few platelet mRNA transcripts are decorated with numerous Ago2-miRNA complexes, and may thus be repressed more strongly than in other cells.
In support of this scheme, SAGE analyses revealed that the average length of platelet mRNA 3′ UTRs is much longer (1,047 nt) than in nucleated cells (492 nt). Moreover, platelets were found to have the longest 3′ UTRs of all examined tissues, with a large margin to the second-ranking fibroblasts (681 nt) 36 . An attractive explanation would be that a system that progressively loses its ability for transcriptional regulation, such as that occurring during platelet maturation from megakaryocytic precursor cells, could compensate for this deficiency by enhancing its capacity for translational control and mRNA a r t i c l e s stability 36 . As such, it is relevant to note that the regulation of the bearded (Brd) box (consensus sequence: AGCUUUA) 37 , which likely involves the formation of RNA-RNA duplexes with complementary sequences found at the 5′ end of certain miRNAs 37 , has been found to be enriched in platelet transcripts 36 .
Regarding the origin of platelet miRNAs, the possibility that they are derived from pri-miRNA transcripts within platelets is highly improbable, considering the absence of a nucleus and that of the nuclear components Drosha and DGCR8, which are required for their maturation. pri-miRNAs are more likely to be encoded by the genome of megakaryocytic precursor cells and converted into pre-miRNAs before platelet formation. Whether pre-miRNAs are actively processed into miRNAs in megakaryocytes and/or platelets remains unclear. The presence of detectable levels of both pre-miRNA species and a Dicer-TRBP2 complex that is functionally competent in miRNA biosynthesis in platelets support the latter possibility, although its significance remains to be determined. On the other hand, the mature miRNA species are much more abundant than their pre-miRNA counterparts, suggesting that a large proportion of the mature miRNA content of platelets may have been inherited directly from megakaryocytes. Nevertheless, both Drosha and Dicer complexes are believed to be involved in the generation of platelet miRNAs, as implied by the overrepresentation of a uracil residue (48%) at the 5′ extremity of these miRNA sequences. This is in accordance with the preference of these RNase III enzymes to cleave 5′ to a uracil.
It has been reported previously that mature miRNAs are bound by Ago proteins 38 and that Ago2 is a crucial component of RNAsilencing effector complexes in human cells 9 . The presence of miRNAs in relatively low-molecular-weight complexes, cofractionating and co-immunoprecipitating with Ago2 and sequence-specific RISC activity, attest to their probable functionality within miRNP complexes in platelets. Although smaller than effector miRNPs of nucleated HeLa cells, the estimated molecular mass of platelet miRNP complexes could not be attributed to the dissociation of a higher-molecularweight complex, and is instead compatible with an Ago2-miRNA complex. The sequence-and site-specific processing of target RNAs in our in vitro cleavage assays imply that the endonucleotidic activity of Ago2 is guided by an associated miRNA. As other groups have established the relevance of using Ago2 immunoprecipitates as a biochemical approach for the identification of miRNA-targeted mRNAs 33, 39, 40 , we opted for this methodology to circumvent the intrinsic limitations associated with working with primary human platelets, including their refractoriness to transfection, which prevents the use and introduction of inhibitory (for example, 2′O-methyl antisense oligonucleotides, short hairpin RNAs, antagomirs) or stimulatory and mimicking (for example, vector-expressing miRNA precursors, synthetic miRNA precursors) molecules traditionally used to identify miRNA targets in more amenable, tractable cellular models.
Using this approach, we identified P2Y 12 mRNA in association with Ago2-miRNA complexes in platelets. Recognized by ADP, an important platelet agonist in vivo, P2Y 12 is a seven-transmembrane domain receptor coupled to G i2 protein that mediates a number of biological processes, such as platelet aggregation, granule secretion and thrombus growth and stability 41 . The experimental validation of the predicted binding site for miR-223 in its natural 3′ UTR context in P2Y 12 mRNA, which is the most abundant platelet receptor for extracellular nucleotides (P2 receptors) expressed at the mRNA level 42 , and the demonstrated ability of miR-223 to regulate gene expression in the context of platelet precursor cells support further the concept that P2Y 12 expression could be regulated by miRNAs, such as miR-223, in human platelets. According to miRBase (http://microrna.sanger.
ac.uk/targets/v5/), at least four additional miRNAs are predicted to target the 3′ UTR of P2Y 12 mRNA: let-7i, miR-21, miR-221 and let-7g. It is therefore possible that miRNAs act coordinately and/or in synergy to regulate P2Y 12 mRNA translation via its 3′ UTR, in which case they could have an important role in modulating platelet function.
In view of our data, we propose a model in which platelets inherit a partial, yet functional, miRNA pathway that is devoid of its nuclear initiation steps through entrapment of the cytoplasmic protein and RNA components of the miRNA machinery during their formation and release from megakaryocyte progenitor cells (Fig. 4e) . The similarities that we observed between the pre-miRNA processing and effector complexes present in megakaryocytes and platelets are supportive of that possibility. In addition, we hypothesize that the miRNA-mediated repression of platelet mRNAs may be lifted upon activation, leading to mRNA translation and protein synthesis, thereby conferring to platelets the ability to respond to physiological stimuli and/or conditions. Considering that activated platelets have been shown to release microvesicles that may exert an extracellular function 43 , it is also tempting to speculate that platelet-derived microparticles (or exosomes) may act as a delivery system for mRNAs 44 as well as miRNAs within the cardiovascular system.
Representing a new class of potential regulatory molecules in platelets, miRNAs lend an additional level of complexity to the control of gene expression in these anucleate elements. As they can potentially fine-tune expression of specific gene products that may be involved in governing platelet reactivity, a dysfunctional miRNA-based regulatory system could lead to the development of serious platelet-related cardiovascular diseases. Our study offers a new perspective on the etiology and therapeutic modulation of platelet function in human diseases.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. 
